Physician profile
Robert Dirom Richards
NPI 1821063884
$3,389.89
in general payments reported to CMS, 2019-2025
24 companies · $94.87 in 2025
The $94.87 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $595 · 2020: $252 · 2021: $619 · 2022: $592 · 2023: $736 · 2024: $501 · 2025: $94.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,332.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,200.29 | 2019-2025 | |
| Janssen Biotech, INC. | $717.44 | 2019-2022 | |
| Pfizer INC. | $219.69 | 2019-2024 | |
| Ironwood Pharmaceuticals, INC | $202.25 | 2020-2024 | Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $165.82 | 2019-2024 | Entyvio |
| Celgene Corporation | $121.71 | 2022-2024 | Zeposia |
| Qol Medical, LLC | $104.77 | 2022-2024 | Sucraid, Sucraid |
| E.R. Squibb & Sons, L.L.C. | $83.47 | 2021 | |
| Daiichi Sankyo INC. | $77.07 | 2022 | |
| Phathom Pharmaceuticals, INC. | $68.26 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $51.92 | 2024 | |
| Intercept Pharmaceuticals, INC. | $51.28 | 2021 | |
| Merck Sharp & Dohme LLC | $45.59 | 2019-2023 | Dificid |
| Medtronic, INC. | $39.61 | 2024-2025 | Gi Genius, Pillcam |
| Capsovision, INC. | $39.39 | 2024 | Capsocam Plus |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.93 | 2021-2024 | Xifaxan |
| Olympus America INC. | $32.85 | 2021 | |
| Ferring Pharmaceuticals INC. | $32.37 | 2020-2022 | |
| Ardelyx, INC. | $21.67 | 2023 | Ibsrela |
| Aimmune Therapeutics, INC. | $21.11 | 2025 | Zenpep |
| Madrigal Pharmaceuticals | $17.71 | 2025 | Rezdiffra |
| Shire North American Group INC | $16.99 | 2019 | |
| Nestle Healthcare Nutrition INC. | $13.14 | 2021 | |
| Ucb, INC. | $11.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Richards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.